Literature DB >> 23100049

Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology.

Ryuichi Harada1, Nobuyuki Okamura, Shozo Furumoto, Tetsuro Tago, Masahiro Maruyama, Makoto Higuchi, Takeo Yoshikawa, Hiroyuki Arai, Ren Iwata, Yukitsuka Kudo, Kazuhiko Yanai.   

Abstract

PURPOSE: Extensive deposition of senile plaques and neurofibrillary tangles in the brain is a pathological hallmark of Alzheimer's disease (AD). Although several PET imaging agents have been developed for in vivo detection of senile plaques, no PET probe is currently available for selective detection of neurofibrillary tangles in the living human brain. Recently, [(18)F]THK-523 was developed as a potential in vivo imaging probe for tau pathology. The purpose of this study was to compare the binding properties of [(18)F]THK-523 and other amyloid imaging agents, including PiB, BF-227 and FDDNP, to synthetic protein fibrils and human brain tissue.
METHODS: In vitro radioligand binding assays were conducted using synthetic amyloid β(42) and K18ΔK280-tau fibrils. Nonspecific binding was determined by the addition of unlabelled compounds at a concentration of 2 μM. To examine radioligand binding to neuropathological lesions, in vitro autoradiography was conducted using sections of AD brain.
RESULTS: [(18)F]THK-523 showed higher affinity for tau fibrils than for Aβ fibrils, whereas the other probes showed a higher affinity for Aβ fibrils. The autoradiographic analysis indicated that [(18)F]THK-523 accumulated in the regions containing a high density of tau protein deposits. Conversely, PiB and BF-227 accumulated in the regions containing a high density of Aβ plaques.
CONCLUSION: These findings suggest that the unique binding profile of [(18)F]THK-523 can be used to identify tau deposits in AD brain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23100049     DOI: 10.1007/s00259-012-2261-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  30 in total

1.  Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease.

Authors:  Nobuyuki Okamura; Takahiro Suemoto; Shozo Furumoto; Masako Suzuki; Hiroshi Shimadzu; Hiroyasu Akatsu; Takayuki Yamamoto; Hironori Fujiwara; Miyako Nemoto; Masahiro Maruyama; Hiroyuki Arai; Kazuhiko Yanai; Tohru Sawada; Yukitsuka Kudo
Journal:  J Neurosci       Date:  2005-11-23       Impact factor: 6.167

2.  2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients.

Authors:  Yukitsuka Kudo; Nobuyuki Okamura; Shozo Furumoto; Manabu Tashiro; Katsutoshi Furukawa; Masahiro Maruyama; Masatoshi Itoh; Ren Iwata; Kazuhiko Yanai; Hiroyuki Arai
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

3.  Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease.

Authors:  Jonghan Shin; Sang-Yoon Lee; So-Hee Kim; Young-Bo Kim; Seong-Jin Cho
Journal:  Neuroimage       Date:  2008-07-23       Impact factor: 6.556

4.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

Authors:  Kooresh Shoghi-Jadid; Gary W Small; Eric D Agdeppa; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Stephen Read; Nagichettiar Satyamurthy; Andrej Petric; Sung-Cheng Huang; Jorge R Barrio
Journal:  Am J Geriatr Psychiatry       Date:  2002 Jan-Feb       Impact factor: 4.105

5.  In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

Authors:  Michelle T Fodero-Tavoletti; David P Smith; Catriona A McLean; Paul A Adlard; Kevin J Barnham; Lisa E Foster; Laura Leone; Keyla Perez; Mikhalina Cortés; Janetta G Culvenor; Qiao-Xin Li; Katrina M Laughton; Christopher C Rowe; Colin L Masters; Roberto Cappai; Victor L Villemagne
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

6.  Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography.

Authors:  Jun Maeda; Bin Ji; Toshiaki Irie; Takami Tomiyama; Masahiro Maruyama; Takashi Okauchi; Matthias Staufenbiel; Nobuhisa Iwata; Maiko Ono; Takaomi C Saido; Kazutoshi Suzuki; Hiroshi Mori; Makoto Higuchi; Tetsuya Suhara
Journal:  J Neurosci       Date:  2007-10-10       Impact factor: 6.167

7.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.

Authors:  Kerryn E Pike; Greg Savage; Victor L Villemagne; Steven Ng; Simon A Moss; Paul Maruff; Chester A Mathis; William E Klunk; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2007-10-10       Impact factor: 13.501

8.  The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component.

Authors:  William E Klunk; Yanming Wang; Guo-feng Huang; Manik L Debnath; Daniel P Holt; Li Shao; Ronald L Hamilton; Milos D Ikonomovic; Steven T DeKosky; Chester A Mathis
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

9.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

10.  A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads.

Authors:  E Braak; H Braak; E M Mandelkow
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

View more
  49 in total

Review 1.  Imaging pathological tau in atypical parkinsonian disorders.

Authors:  Sarah Coakeley; Antonio P Strafella
Journal:  Curr Opin Neurol       Date:  2015-08       Impact factor: 5.710

2.  In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging.

Authors:  Jorge R Barrio; Gary W Small; Koon-Pong Wong; Sung-Cheng Huang; Jie Liu; David A Merrill; Christopher C Giza; Robert P Fitzsimmons; Bennet Omalu; Julian Bailes; Vladimir Kepe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

Review 3.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

4.  Current understanding of chronic traumatic encephalopathy.

Authors:  Robert A Stern; Ann C McKee; Christine M Baugh; Clifford A Robbins
Journal:  Curr Treat Options Neurol       Date:  2014-09       Impact factor: 3.598

Review 5.  Tau PET imaging in Alzheimer's disease.

Authors:  Nobuyuki Okamura; Ryuichi Harada; Shozo Furumoto; Hiroyuki Arai; Kazuhiko Yanai; Yukitsuka Kudo
Journal:  Curr Neurol Neurosci Rep       Date:  2014-11       Impact factor: 5.081

Review 6.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

7.  Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.

Authors:  Suzanne L Baker; Samuel N Lockhart; Julie C Price; Mark He; Ronald H Huesman; Daniel Schonhaut; Jamie Faria; Gil Rabinovici; William J Jagust
Journal:  J Nucl Med       Date:  2016-09-01       Impact factor: 10.057

Review 8.  Harnessing the immune system for treatment and detection of tau pathology.

Authors:  Erin E Congdon; Senthilkumar Krishnaswamy; Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 9.  Genetics of Frontotemporal Dementia.

Authors:  Diana A Olszewska; Roisin Lonergan; Emer M Fallon; Tim Lynch
Journal:  Curr Neurol Neurosci Rep       Date:  2016-12       Impact factor: 5.081

Review 10.  Imaging frontotemporal lobar degeneration.

Authors:  Janine Diehl-Schmid; Oezguer A Onur; Jens Kuhn; Traugott Gruppe; Alexander Drzezga
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.